US Pharma MarketingNovartis takes rights to Abogen
Novartis pays Abogen $575M upfront for an mRNA-encoded CD19xCD3 T cell engager, with up to $7.2B in milestones. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies…
Novartis will pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to an early-stage CD19xCD3 T cell engager, which is the Chinese biotech's lead asset.
Abogen could get up to about $7.2 billion further ...
Source: Endpoints News